cholestyramine powder for suspension NDC 72162-1834

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-1834Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-1834Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-1834-2	72162183402	368.76 g in 1 JAR (72162-1834-2)Marketed from Mar 8, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): cholestyramine powder for suspension
Generic name (nonproprietary): cholestyramine powder for suspension
Active ingredients: Cholestyramine — 4 g/8.78g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211856
Marketing start: Oct 20, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 72162-1834_ecd4d973-d8bd-4af5-9bd4-4ea7f347a368SPL ID ecd4d973-d8bd-4af5-9bd4-4ea7f347a368SPL set ID 31d04422-f159-42ba-8eb5-b0ec1dbc52f9RxCUI 848943UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162183402 followed by a unit qualifier and the quantity

Package 72162-1834-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 26, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular di…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211856

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211856
Product	Strength	Form · route	Labeler	Product NDC
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Bryant Ranch Prepack	71335-2902
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Bryant Ranch Prepack	63629-9196
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Ascend Laboratories, LLC	67877-298